Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Cyclophosphamide 50mg|DRUG: Pembrolizumab 100 MG in 4 ML Injection
Sponsor: Centre Leon Berard
Collaborators: Merck Sharp & Dohme LLC